Evidence map›Paper›PMID 32781001›Full record

ArticleExperimental neurology2020

Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout.

Philip H Iffland, Allan E Barnes, Marianna Baybis, Peter B Crino

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Tuberous sclerosis complex.Nature reviews. Disease primers · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Philip H IfflandDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Allan E BarnesDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Marianna BaybisDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Peter B CrinoDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States of America. Electronic address: pcrino@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

Identification and molecular characterization of somatic mutations in MCDR01NS094596 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Peter B Crino, Erin L HEINZEN · 2016 to 2026
$5.9M
The Role of GATOR1 in Cortical MalformationsR01NS099452 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI CRINO, PETER B · 2017 to 2021
$1.7M
NINDS NIH HHS R01 NS094596NINDS NIH HHS R01 NS099452
6 · The paper itself

Abstract

TSC1 or TSC2 mutations cause Tuberous Sclerosis Complex (TSC), and lead to mechanistic target of rapamycin (mTOR) hyperactivation evidenced by hyperphosphorylation of ribosomal S6 protein and 4-elongation factor binding protein 1 (4E-BP1). Amino acid (AA) levels modulate mTOR-dependent S6 and 4E-BP1 phosphorylation in non-neural cells, but this has not been comprehensively investigated in neurons. The effects of AA levels on mTOR signaling and S6 and 4E-BP1 phosphorylation were analyzed in Tsc2 and Depdc5 (a distinct mTOR regulatory gene associated with epilepsy) CRISPR-edited Neuro2a (N2a) cells and differentiated neurons. Tsc2 or Depdc5 knockout (KO) led to S6 and 4E-BP1 hyperphosphorylation and cell soma enlargement, but while Tsc2 KO N2a cells exhibited reduced S6 phosphorylation (Ser240/244) and cell soma size after incubation in AA free (AAF) media, Depdc5 KO cells did not. Using a CFP/YFP FRET-biosensor coupled to 4E-BP1, we assayed 4E-BP1 phosphorylation in living N2a cells and differentiated neurons following Tsc2 or Depdc5 KO. AAF conditions reduced 4E-BP1 phosphorylation in Tsc2 KO N2a cells but had no effect in Depdc5 KO cells. Rapamycin blocked S6 protein phosphorylation but had no effect on 4E-BP1 phosphorylation, following either Tsc2 or Depdc5 KO. Confocal imaging demonstrated that AAF media promoted movement of mTOR off the lysosome, functionally inactivating mTOR, in Tsc2 KO but not Depdc5 KO cells, demonstrating that AA levels modulate lysosomal mTOR localization and account, in part, for differential effects of AAF conditions following Tsc2 versus Depdc5 KO. AA levels and rapamycin differentially modulate S6 and 4E-BP1 phosphorylation and mTOR lysosomal localization in neurons following Tsc2 KO versus Depdc5 KO. Neuronal mTOR signaling in mTOR-associated epilepsies may have distinct responses to mTOR inhibitors and to levels of cellular amino acids.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCell Cycle ProteinsCell Line, TumorGene Knockout TechniquesGTPase-Activating ProteinsImmunosuppressive AgentsMiceNeuronsPhosphorylationSirolimusTuberous Sclerosis Complex 2 ProteinAdaptor Proteins, Signal TransducingCell Cycle ProteinsDepdc5 protein, mouseEIF4EBP1 protein, humanGTPase-Activating ProteinsImmunosuppressive AgentsSirolimusTsc2 protein, mouseTuberous Sclerosis Complex 2 ProteinCortical malformationsEpilepsyGATOR1mTORopathiesTuberous sclerosis complex

Identifiers

PMID32781001
PMCPMC8170708
OpenAlexW3048104353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.